Guidance on Anti-Infective Non-Inferiority Margins May Not Be Clear-Cut

FDA is expected to provide some much-desired clarity on its policy for non-inferiority margins in clinical trials for anti-infectives at this week's advisory committee meeting. But the end result may not be the concrete answer that industry is hoping for